Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community

Karen Lee Ann Chen, Xiaoji Liu, Yiru Chen Zhao, Kadriye Hieronymi, Gianluigi Rossi, Loretta Sue Auvil, Michael Welge, Colleen Bushell, Rebecca Lee Smith, Kathryn E. Carlson, Sung Hoon Kim, John A. Katzenellenbogen, Michael Joseph Miller, Zeynep Madak-Erdogan

Research output: Contribution to journalArticle

Abstract

Conjugated estrogens (CE) and Bazedoxifene (BZA) combination is used to alleviate menopause-associated symptoms in women. CE+BZA undergo first-pass-metabolism in the liver and deconjugation by gut microbiome via β-glucuronidase (GUS) enzyme inside the distal gut. To date, the impact of long-term exposure to CE+BZA on the gut microbiome or GUS activity has not been examined. Our study using an ovariectomized mouse model showed that CE+BZA administration did not affect the overall cecal or fecal microbiome community except that it decreased the abundance of Akkermansia, which was identified as a fecal biomarker correlated with weight gain. The fecal GUS activity was reduced significantly and was positively correlated with the abundance of Lactobacillaceae in the fecal microbiome. We further confirmed in Escherichia coli K12 and Lactobacillus gasseri ADH that Tamoxifen-, 4-hydroxy-Tamoxifen- and Estradiol-Glucuronides competed for GUS activity. Our study for the first time demonstrated that long-term estrogen supplementation directly modulated gut microbial GUS activity. Our findings implicate that long-term estrogen supplementation impacts composition of gut microbiota and microbial activity, which affects estrogen metabolism in the gut. Thus, it is possible to manipulate such activity to improve the efficacy and safety of long-term administered estrogens for postmenopausal women or breast cancer patients.

Original languageEnglish (US)
Article number8166
JournalScientific reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Conjugated (USP) Estrogens
Microbiota
Glucuronidase
Estrogens
Lactobacillaceae
Escherichia coli K12
Glucuronides
Tamoxifen
Menopause
Weight Gain
Estradiol
Biomarkers
bazedoxifene
Breast Neoplasms
Safety
Liver
Enzymes
Gastrointestinal Microbiome

ASJC Scopus subject areas

  • General

Cite this

Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community. / Chen, Karen Lee Ann; Liu, Xiaoji; Zhao, Yiru Chen; Hieronymi, Kadriye; Rossi, Gianluigi; Auvil, Loretta Sue; Welge, Michael; Bushell, Colleen; Smith, Rebecca Lee; Carlson, Kathryn E.; Kim, Sung Hoon; Katzenellenbogen, John A.; Miller, Michael Joseph; Madak-Erdogan, Zeynep.

In: Scientific reports, Vol. 8, No. 1, 8166, 01.12.2018.

Research output: Contribution to journalArticle

Chen, Karen Lee Ann ; Liu, Xiaoji ; Zhao, Yiru Chen ; Hieronymi, Kadriye ; Rossi, Gianluigi ; Auvil, Loretta Sue ; Welge, Michael ; Bushell, Colleen ; Smith, Rebecca Lee ; Carlson, Kathryn E. ; Kim, Sung Hoon ; Katzenellenbogen, John A. ; Miller, Michael Joseph ; Madak-Erdogan, Zeynep. / Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{b0b172a6a6134f9d9d816ae5baa86ce7,
title = "Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community",
abstract = "Conjugated estrogens (CE) and Bazedoxifene (BZA) combination is used to alleviate menopause-associated symptoms in women. CE+BZA undergo first-pass-metabolism in the liver and deconjugation by gut microbiome via β-glucuronidase (GUS) enzyme inside the distal gut. To date, the impact of long-term exposure to CE+BZA on the gut microbiome or GUS activity has not been examined. Our study using an ovariectomized mouse model showed that CE+BZA administration did not affect the overall cecal or fecal microbiome community except that it decreased the abundance of Akkermansia, which was identified as a fecal biomarker correlated with weight gain. The fecal GUS activity was reduced significantly and was positively correlated with the abundance of Lactobacillaceae in the fecal microbiome. We further confirmed in Escherichia coli K12 and Lactobacillus gasseri ADH that Tamoxifen-, 4-hydroxy-Tamoxifen- and Estradiol-Glucuronides competed for GUS activity. Our study for the first time demonstrated that long-term estrogen supplementation directly modulated gut microbial GUS activity. Our findings implicate that long-term estrogen supplementation impacts composition of gut microbiota and microbial activity, which affects estrogen metabolism in the gut. Thus, it is possible to manipulate such activity to improve the efficacy and safety of long-term administered estrogens for postmenopausal women or breast cancer patients.",
author = "Chen, {Karen Lee Ann} and Xiaoji Liu and Zhao, {Yiru Chen} and Kadriye Hieronymi and Gianluigi Rossi and Auvil, {Loretta Sue} and Michael Welge and Colleen Bushell and Smith, {Rebecca Lee} and Carlson, {Kathryn E.} and Kim, {Sung Hoon} and Katzenellenbogen, {John A.} and Miller, {Michael Joseph} and Zeynep Madak-Erdogan",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-26506-1",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community

AU - Chen, Karen Lee Ann

AU - Liu, Xiaoji

AU - Zhao, Yiru Chen

AU - Hieronymi, Kadriye

AU - Rossi, Gianluigi

AU - Auvil, Loretta Sue

AU - Welge, Michael

AU - Bushell, Colleen

AU - Smith, Rebecca Lee

AU - Carlson, Kathryn E.

AU - Kim, Sung Hoon

AU - Katzenellenbogen, John A.

AU - Miller, Michael Joseph

AU - Madak-Erdogan, Zeynep

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Conjugated estrogens (CE) and Bazedoxifene (BZA) combination is used to alleviate menopause-associated symptoms in women. CE+BZA undergo first-pass-metabolism in the liver and deconjugation by gut microbiome via β-glucuronidase (GUS) enzyme inside the distal gut. To date, the impact of long-term exposure to CE+BZA on the gut microbiome or GUS activity has not been examined. Our study using an ovariectomized mouse model showed that CE+BZA administration did not affect the overall cecal or fecal microbiome community except that it decreased the abundance of Akkermansia, which was identified as a fecal biomarker correlated with weight gain. The fecal GUS activity was reduced significantly and was positively correlated with the abundance of Lactobacillaceae in the fecal microbiome. We further confirmed in Escherichia coli K12 and Lactobacillus gasseri ADH that Tamoxifen-, 4-hydroxy-Tamoxifen- and Estradiol-Glucuronides competed for GUS activity. Our study for the first time demonstrated that long-term estrogen supplementation directly modulated gut microbial GUS activity. Our findings implicate that long-term estrogen supplementation impacts composition of gut microbiota and microbial activity, which affects estrogen metabolism in the gut. Thus, it is possible to manipulate such activity to improve the efficacy and safety of long-term administered estrogens for postmenopausal women or breast cancer patients.

AB - Conjugated estrogens (CE) and Bazedoxifene (BZA) combination is used to alleviate menopause-associated symptoms in women. CE+BZA undergo first-pass-metabolism in the liver and deconjugation by gut microbiome via β-glucuronidase (GUS) enzyme inside the distal gut. To date, the impact of long-term exposure to CE+BZA on the gut microbiome or GUS activity has not been examined. Our study using an ovariectomized mouse model showed that CE+BZA administration did not affect the overall cecal or fecal microbiome community except that it decreased the abundance of Akkermansia, which was identified as a fecal biomarker correlated with weight gain. The fecal GUS activity was reduced significantly and was positively correlated with the abundance of Lactobacillaceae in the fecal microbiome. We further confirmed in Escherichia coli K12 and Lactobacillus gasseri ADH that Tamoxifen-, 4-hydroxy-Tamoxifen- and Estradiol-Glucuronides competed for GUS activity. Our study for the first time demonstrated that long-term estrogen supplementation directly modulated gut microbial GUS activity. Our findings implicate that long-term estrogen supplementation impacts composition of gut microbiota and microbial activity, which affects estrogen metabolism in the gut. Thus, it is possible to manipulate such activity to improve the efficacy and safety of long-term administered estrogens for postmenopausal women or breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85047726244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047726244&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-26506-1

DO - 10.1038/s41598-018-26506-1

M3 - Article

C2 - 29802368

AN - SCOPUS:85047726244

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 8166

ER -